Emily.AI: Personalized Oxygen Therapy Earns Global AI Recognition

Following a competitive process involving more than 500 projects from around the world, Emily.AI, Quirónsalud’s first explainable artificial intelligence (AI)-based medical device, was a global finalist at the AI ​​for Good Innovation Factory Grand Finale, held during the AI ​​for Good Global Summit 2026 in Geneva, Switzerland, and organized by the International Telecommunication Union (ITU).

Emily.AI incorporates data and predictive capabilities to adapt oxygen flow to each patient’s specific needs, allowing for real-time monitoring and personalization of oxygen therapy.

Developed by a Catalan startup, the design of Emily.AI has been based on real observations of the Intermediate Respiratory Care Unit ( UCIR ) of the Jiménez Díaz University Hospital Foundation.

There, more than 50 patients with respiratory failure requiring titrated oxygen therapy, sufficient hemodynamic stability to tolerate the session, and a ventilatory pattern compatible with reliable pulse oximetry monitoring, have already received oxygen therapy controlled by this technology with “excellent results” in three clinical scenarios covered: patients in spontaneous breathing, in non-invasive mechanical ventilation and in invasive mechanical ventilation.

Emily.AI has the ability to adapt the oxygen flow to the actual needs of each patient to control oxygen therapy in real time

This technology “combines clinical leadership, multidisciplinary work, excellence in explainable AI, medical hardware, software architecture, entrepreneurial vision and regulatory rigor to transform oxygen therapy into a personalized, predictive, automated and precision therapy ,” says Daniel Oliva , director and founder of Emily.AI, the company that developed the device.

The Emily.AI device also allows for remote control and monitoring, unifying all connected patients in real time and thus reducing the clinical workload. The system continuously monitors the patient’s physiological parameters, anticipates changes in oxygen saturation, and automatically adjusts the oxygen flow in real time to keep each patient within their optimal therapeutic range.

Compliance with the SDGs

Thanks to the integration of AI, medical hardware, and continuous monitoring, Emily.AI primarily contributes to Sustainable Development Goal (SDG) 3 (Good Health and Well-being) by improving the safety and efficacy of oxygen therapy, keeping patients within their optimal oxygen saturation range, detecting respiratory deterioration early, and promoting higher quality care both in the hospital and at home.

Emily.Ai device also contributes to SDG 9 (Industry, Innovation and Infrastructure) by incorporating technological innovation into treatment; to SDG 10 (Reduced Inequalities) by bringing specialized respiratory care to any healthcare setting; and to SDG 12 (Responsible Consumption and Production) by optimizing the use of medical oxygen and reducing the waste of an essential resource.

The device also reinforces SDG 8 (Decent Work and Economic Growth) by reducing the workload of healthcare professionals through the intelligent automation of oxygen titration; and contributes to SDG 17 (Partnerships for the Goals) thanks to a collaborative model that integrates hospitals, research centers, universities, public administrations and technology companies.

__

(Featured image by fernando zhiminaicela via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.